Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
2.
Joint Bone Spine ; 89(5): 105380, 2022 10.
Article in English | MEDLINE | ID: mdl-35490940

ABSTRACT

INTRODUCTION: Vaccination is considered as a cornerstone of the management of COVID-19 pandemic. However, while vaccines provide a robust protection in immunocompetent individuals, the immunogenicity in patients with inflammatory rheumatic diseases (IRD) is not well established. METHODS: A monocentric observational study evaluated the immunogenicity of a two-dose regimen vaccine in adult patients with IRD (n=123) treated with targeted or biological therapies. Serum IgG antibody levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins were measured after the second vaccination. In addition, a search for observational studies performed in IRD under biologic or targeted therapies up to September 31, 2021 (PROSPERO registration number: CRD42021259410) was undertaken in publication databases, preprint servers, and grey literature sources. Studies that reported sample size, study date, location, and seroprevalence estimate were included. A meta-analysis was conducted to identify demographic differences in the prevalence of SARS-CoV-2 antibodies. RESULTS: Of 123 patients (median age 66 IQR 57-75), 69.9% have seroconverted after vaccination. Seroconverted patients were older than non-seroconverted ones in our cohort. Rituximab was associated with a significantly low antibody response. Besides, we identified 20 seroprevalence studies in addition to our cohort including 4423 participants in 11 countries. Meta-analysis confirmed a negative impact of rituximab on seroconversion rate and suggested a less substantial effect of abatacept, leflunomide and methotrexate. CONCLUSION: Rituximab impairs serological response to SARS-CoV-2 vaccines in patients with IRD. This work suggests also a negative impact of abatacept, methotrexate or leflunomide especially when associated to biological therapy.


Subject(s)
Antirheumatic Agents , COVID-19 , Rheumatic Diseases , Abatacept/therapeutic use , Adult , Aged , Antirheumatic Agents/therapeutic use , COVID-19/prevention & control , COVID-19 Vaccines , Cohort Studies , Humans , Immunoglobulin G , Leflunomide/therapeutic use , Methotrexate/therapeutic use , Observational Studies as Topic , Pandemics , Rheumatic Diseases/drug therapy , Rituximab/therapeutic use , SARS-CoV-2 , Seroepidemiologic Studies , Serotonin Agents/therapeutic use , Spike Glycoprotein, Coronavirus/therapeutic use , Vaccination
3.
Invest New Drugs ; 28(1): 76-82, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19205623

ABSTRACT

OBJECTIVE: Selecting patients for phase 1 studies remains challenging. Given the lack of clear and reliable guidance for the estimation of life expectancy, we retrospectively assessed predictive factors of early death (within 90 days following inclusion) among these patients. METHODS: Two hundred fifty-seven consecutive cancer patients enrolled in phase I studies investigating cytotoxics at Oscar Lambret Cancer Center and Institut Claudius Regaud were included in the development database. Univariate and multivariate analyses (logistic regression model) were undertaken to determine the prognostic factors. A probability tree described the rate of early death in the different prognostic subgroups. This prognostic model was then evaluated on a second independent cohort of 128 patients treated at Léon Bérard Cancer Center. RESULTS: The median overall survival was 8.4 months in the dataset population, and the rate of early death was 15%. In multivariate analysis, the two prognostic factors for early death were albumin <38 g/l (OR = 5.21) and lymphocytes <700/mm(3) (OR = 3.88). According to these two parameters, three prognostic subgroups were defined with early death rates of, respectively, 8/121 (6%), 19/119 (16%) and 13/17 (76%). In the validation dataset, the rates of early death according to three prognostic groups were 13/68 (19%), 20/57 (35%) and 3/3 (100%), respectively. CONCLUSION: We do not recommend the enrolment of patients with albumin level below 38g/l and lymphocytes count below 700/mm(3), in phase 1 trial investigating cytotoxics. Our model is helpful to discriminate "patients with reasonable life expectancy" as defined in most phase 1 protocols.


Subject(s)
Antineoplastic Agents/pharmacology , Clinical Trials, Phase I as Topic , Models, Statistical , Neoplasms/mortality , Adolescent , Adult , Aged , Aged, 80 and over , Cell Death/drug effects , Female , Humans , Male , Middle Aged , Multivariate Analysis , Prognosis , Reproducibility of Results , Survival Analysis , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...